Advisory Panel To Consider Vandetanib's New Life In Niche Thyroid Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
After missing the boat in non-small cell lung cancer, AstraZeneca has repositioned the drug for the rare advanced medullary thyroid cancer.
You may also be interested in...
Toxicity Of AstraZeneca's Vandetanib Expected Focus For FDA Advisory Committee
FDA will ask its Oncologic Drugs Advisory Committee at a Dec. 2 meeting whether the thyroid cancer drug should be limited to only those patients with progressive, symptomatic disease and if post-marketing studies are needed to determine the optimal dose.
Toxicity Of AstraZeneca's Vandetanib Expected Focus For FDA Advisory Committee
FDA will ask its Oncologic Drugs Advisory Committee at a Dec. 2 meeting whether the thyroid cancer drug should be limited to only those patients with progressive, symptomatic disease and if post-marketing studies are needed to determine the optimal dose.
Bristol Melanoma Drug's Advisory Panel Delayed Following Review Date Delay
Additional Phase III data for ipilimumab might be available by next year, and an early March advisory committee date now looks likely, given the rescheduled PDUFA date of March 26, 2011.